🇺🇸 FDA

Company profile · Sponsor

Travere

Travere Therapeutics

TVTX · NYSE pharma SAN DIEGO, CA, USA
Pipeline
13
Drugs
1
Patents
1

Quick answer

Travere (TVTX) is a pharma company. headquartered in SAN DIEGO, CA, USA. listed on NYSE. NovaPharmaNews links 13 pipeline programs, 1 drug, and 1 patent to this profile..

Company facts

Ticker TVTX
Exchange NYSE
Company type pharma
Headquarters SAN DIEGO, CA, USA
SEC CIK 0001438533

Pipeline (13)

Search pipeline →

  1. Fosmetpantotenate

    Travere

    Pantothenate Kinase-Associated Neurodegeneration

    phase 3 small molecule terminated

    1 trial

  2. IRBESARTAN, DAPAGLIFLOZIN, Sparsentan_DF3, Sparsentan_DF2

    Travere

    Immunoglobulin A Nephropathy (IgAN)

    phase 3 small molecule active

    1 trial

  3. Pegtibatinase

    Travere

    Homocystinuria

    phase 3 small molecule active

    3 trials

  4. Pegtibatinase, 0.9 % sodium chloride saline solution (NaCL)

    Travere

    Classical Homocystinuria

    phase 3 small molecule active

    1 trial

  5. Sparsentan_DF2, IRBESARTAN, Sparsentan_DF3

    Travere

    Focal segmental glomerulosclerosis (FSGS)

    phase 3 small molecule active

    1 trial

  6. sparsentan

    Travere

    Immunoglobulin A Nephropathy

    phase 3 small molecule active

    3 trials

  7. sparsentan

    Travere

    Focal Segmental Glomerulosclerosis

    phase 3 small molecule active

    2 trials

  8. RE-021 (Sparsentan)

    Travere

    Focal Segmental Glomerulosclerosis

    phase 2 small molecule completed

    1 trial

  9. Sparsentan

    Travere

    ANCA Associated Vasculitis

    phase 2 small molecule active

    1 trial

  10. Sparsentan_DF3, Sparsentan_DF2, Sparsentan_DF4

    Travere

    Proteinuric glomerular diseases including: •Focal segmental glomerulosclerosis (FSGS) •Minimal change disease (MCD) •Immunoglobulin A nephropathy (IgAN) •Immunoglobulin A vasculitis (IgAV) •Alport syndrome (AS)

    phase 2 small molecule active

    1 trial

  11. RE-021, sparsentan

    Travere

    Healthy Subjects

    phase 1 small molecule completed

    1 trial

  12. sparsentan

    Travere

    Proteinuric Renal Disease

    phase 1 small molecule active

    1 trial

  13. Sparsentan

    Travere

    Proteinuria

    approved small molecule active

    1 trial

Drugs (1)

Search drugs →

  1. sparsentan

    FILSPARI

    ORAL approved

    C09XX01

Patents (1)

Search patents →

  1. US 11207299

    Biphenyl sulfonamide compounds for the treatment of type IV collagen diseases

    Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Travere?

Travere (TVTX) is a pharma company. headquartered in SAN DIEGO, CA, USA. listed on NYSE. NovaPharmaNews links 13 pipeline programs, 1 drug, and 1 patent to this profile..

What pipeline programs does Travere sponsor?

We track 13 ClinicalTrials.gov-linked programs for Travere, including Fosmetpantotenate and 12 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Travere company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.